Teva Pharmaceutical Industries Ltd. (TEVA)

12.68
0.88 7.50
NYSE : Health Technology
Prev Close 11.80
Open 12.51
Day Low/High 12.01 / 12.71
52 Wk Low/High 6.07 / 13.76
Volume 17.34M
Avg Volume 10.87M
Exchange NYSE
Shares Outstanding 1.10B
Market Cap 12.57B
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
Teva May Have Found a Cure for Last Year

Teva May Have Found a Cure for Last Year

This pharma company is still making lots of money and its stock is too cheap to pass up.

Why Teva Pharmaceuticals Shares Are Losing Steam

Why Teva Pharmaceuticals Shares Are Losing Steam

Teva Pharmaceuticals plunged on Friday amid weaker-than-expected 2017 guidance.

BioDelivery Sciences Showing Strength

Not much action in the markets since our last update with the major indices continuing to grind slightly higher as we try to close out a solid first trading week of 2017 on a high note. Think Teva Pharmaceuticals getting oversold today on slightly r...

Here's What to Look for at the J.P. Morgan Healthcare Conference

Here's What to Look for at the J.P. Morgan Healthcare Conference

The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.

Biotech Should Witness M&A's Return in 2017

Biotech Should Witness M&A's Return in 2017

Drug giants with money to spend and a friendlier regulatory environment should spur deals.

Biotech Poised for Rebound

Biotech Poised for Rebound

If M&A picks up and Trump doesn't tweet about excessively high drug prices, there should be bounce.

Biotech Poised for Rebound

Biotech Poised for Rebound

If M&A picks up and Trump doesn't tweet about excessively high drug prices, there should be bounce.

Expect Some Big-Cap Biotech Love in 2017

We touched briefly on housing in our first post this morning. There are still some cheap home-building stocks if the housing market continues to improve, which I expect as I believe economic growth will pick up in 2017. I have done well with this se...

Stop Listening to 'The Market'

Stop Listening to 'The Market'

Here are stocks with solid fundamentals at some of the best absolute entry points in years.

Teva Pharmaceutical Is Down to Key Support. Did I Say Key?

Teva Pharmaceutical Is Down to Key Support. Did I Say Key?

Wait for a bounce and then a retest before stepping up to buy.

Some 'January Effect' Stock Picks

Some 'January Effect' Stock Picks

Small-caps could also benefit from abating tax-loss selling.

Allergan Could Pay $1 Billion for Chase Pharma

Allergan Could Pay $1 Billion for Chase Pharma

'Milestone payments' could boost deal's $125 million announced price.

Some Black Friday Stock Market Buys

An Uninspired Start

And we are off. The market has opened opens slightly lower across the board. We're seeing some profit taking early on in stocks and sectors that have done extremely well since the election. United Rentals , after massive run over the past week, is d...

Teva downgraded at Morgan Stanley

Greetings From Your Pinch Hitter, Bret Jensen

It is good to be standing in for Doug Kass this Wednesday. We saw somewhat of a snapback rally yesterday in some of the sectors that have underperformed since the unexpected election results last week. Technology was up nearly 1.5% within a decent d...

Teva downgraded at Jefferies

Cramer: This Is No Time to Dog-Paddle

Cramer: This Is No Time to Dog-Paddle

In these market crosscurrents, it's tough to go with the flow.

Biopharma: It's Darkest Before the Dawn

Biopharma: It's Darkest Before the Dawn

Thursday felt a lot like capitulation in this space. I was buying.

My Takeaways and Observations (Early Edition)

I have been warning about weakening breadth and narrow leadership for weeks and months.   What have we gotten? Eight straight days (in a row) down for the first time since 2008.   But, with stocks suffering from election uncertainties and given the ...

3 Small-Caps Bucking the Downtrend

3 Small-Caps Bucking the Downtrend

News announcements from these companies are supportive of continued strength.

3 Small-Caps Bucking the Downtrend

3 Small-Caps Bucking the Downtrend

News announcements from these companies is supportive of continued strength.

Jim Cramer: Allergan a Winner in a Tough Time to Own Drug Stocks

Jim Cramer: Allergan a Winner in a Tough Time to Own Drug Stocks

Allergan is a winner but it is a bad time to own drug stocks, says Jim Cramer.

Pharma Should Offer Post-Election Bargains

Pharma Should Offer Post-Election Bargains

The likely continuation of a split government should help the sector recover from its recent beat-down.

FDA Puts Hold on Regeneron Pain-Drug Study

FDA Puts Hold on Regeneron Pain-Drug Study

Shares of Regeneron Pharmaceuticals were lower Monday after The Food and Drug Administration put a drug study on hold.

Teva estimates, target cut at Leerink

These Dogs May Soon Have Their Day

These Dogs May Soon Have Their Day

Problems have hit some favorite names, but opportunities are becoming apparent.

Andrew Left Says Trump and Clinton Agree on Just One Thing

Andrew Left Says Trump and Clinton Agree on Just One Thing

Attacking Big Pharma price gougers may be all that unifies the candidates ahead of tonight's debate.

Teva: This Is No Generic Downtrend

Teva: This Is No Generic Downtrend

There are no bullish divergences of consequence to suggest that the stock might be poised to rally.

5 Healthy Pharma and Biotech Plays

5 Healthy Pharma and Biotech Plays

These stocks look good as seasonal volatility sets in.